Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Cell Biol Toxicol. 2020 Sep 26;37(3):461–478. doi: 10.1007/s10565-020-09557-x

Figure 1. Availability of CD34-expressing cells with advanced disease in neuroblastoma patients:

Figure 1.

(a) Representative microphotographs showing surface expression of CD34 in human NB [Magnification 20x; Insert, 40x], Histograms constructed from Aperio TMA image analysis of CD34 strong positivity identified (b) significant association of CD34 expression with advanced disease stage; (c) profound correlation of high CD34 expression with N-MYC amplification compared with N-MYC non-amplified subset; (d) acquired gain of CD34-expressing cells in progressive tumors after intensive multimodal clinical therapy (PD, progressive disease) compared with the disease at diagnosis (Dx); (e) acquired gain of CD34-expressing cells in progressive tumors after IMCT in patients presenting with various stages of disease; (f) no significant association with primary or metastatic disease; and (g) the levels of CD34-expressing cells in NB tumors from various recovery sites, irrespective of the primary or metastatic status. Group-wise comparisons were performed with GraphPad Prism. P values of less than 0.05 were considered significant.